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An important excipient used to overcome poor solubility is cyclodextrin. However, data in the literature
suggest that excessive overdosing of cyclodextrins can decrease the absorption of compounds admin-
istered with cyclodextrins, due to their lack of release from the complex. g-Cyclodextrin is digestible in
contrast to b-cyclodextrins. This could potentially limit the sensitivity toward overdose, which was
evaluated using benzo[a]pyrene in this study, in which rats were administered benzo[a]pyrene and
different doses of the 2 cyclodextrins. Both cyclodextrins lowered the area under the curve and therefore
the absorption of benzo[a]pyrene by up to a factor of 2 when dosed in high concentrations, thus indi-
cating that overdosing of cyclodextrins may limit the oral absorption of a compound. This limitation may
be artificial because the molar ratio of benzo[a]pyrene:cyclodextrin was >1:50,000 at the concentration
where a significant decrease in the absorption was observed. No difference was observed between
the 2 cyclodextrins, so digestibility seemed less important. More interesting was that the decrease in
absorption was relatively small when compared with literature values, suggesting that the effect of
overdosing a compound with cyclodextrins was lower than anticipated.
© 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.Introduction
A frequently encountered problem in drug discovery and
development is the low solubility of drug candidates and a large
proportion of drugs in development therefore belong to class II
or IV according to the Biopharmaceutical Classification System.1
For compounds with a low aqueous solubility, dissolution in the
intestinal fluid may be rate limiting and could potentially limit
their bioavailability. In clinical use, the poor bioavailability of a
drug might result in limited therapeutic potential leading to
insufficient clinical outcomes; hence to facilitate the development
of these difficult-to-formulate compounds, various technological
approaches may be applied to enhance the absorption of poorly
water-soluble drugs. These approaches include changing the
chemical structure (e.g., developing a prodrug) or formulation
strategies (e.g., physical modifications such as particle sizefrom the authors by request
2015.10.027.
-3643-3596; Fax: þ45-3643-
®. Published by Elsevier Inc. All rireduction, lipid-based formulations, amorphous systems, and
complexation with cyclodextrins).1-3
Cyclodextrins are useful functional excipients, which are used
widely both in development and in several marketed pharmaceu-
tical products.4-7 The basis for this popularity is the ability of
cyclodextrins to interact with poorly water-soluble drugs forming
noncovalent dynamic inclusion complexes. On account of this, an
increase in the apparent water solubility of the compounds is
observed leading to an enhanced bioavailability when adminis-
tered orally.6,8 Commonly used cyclodextrins consist of 6, 7, or 8
glycosidic bonded glucose molecules, denoted a-, b-, and g-cyclo-
dextrins, respectively.9 The a- and b-cyclodextrins are digested and
absorbed to a very limited extent.8,10 The drug compound needs to
be displaced from the complex with cyclodextrin complex before it
can be absorbed into the epithelia and from there enter the sys-
temic blood circulation.11Westerberg andWiklund12 have reported
that oral coadministration of excess b-cyclodextrin significantly
decreases the oral bioavailability of benzo[a]pyrene in rats. Benzo
[a]pyrene is a poorly water-soluble compound that can be solubi-
lized by cyclodextrins and Westerberg and Wiklund12 suggested
that this phenomenon was a consequence of the strong stability
constant between the cyclodextrin and benzo[a]pyrene.12 Cyclo-
dextrins cannot be absorbed by the gastrointestinal mucosa andghts reserved.
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membrane. The extent of absorption thus depends on the dissoci-
ation equilibrium, which is shifted toward the complex if the sta-
bility constant is high.13 In addition to this effect, the dissociation
equilibrium may be influenced by the presence of other hydro-
phobic compounds present in the intestinal chyme that can
compete for the cyclodextrin cavity, thereby displacing the com-
pound. Bile salts are the most extensively studied competitor, and
are present in high concentrations in the intestine. Furthermore,
bile-depleted animals have shown a lower absorption of com-
pounds from cyclodextrin complex solutions than naive ani-
mals.11,14 A possible explanation for the decreased absorption,
when high cyclodextrin amounts were dosed could therefore be
due to the strong complexation affinity between cyclodextrins and
the drug compound, so that bile salts cannot compete when
extensive amounts of cyclodextrin are administered.
Lumholdt et al.10 have reported an additional mechanism for
drug dissociation from cyclodextrin complexes. These authors
showed that g-cyclodextrin was a substrate for enzymatic degra-
dation by a-amylases, while b-cyclodextrin and hydroxypropyl-b-
cyclodextrin (HP-b-cyclodextrin) were degraded to a very limited
extent. The ability of g-cyclodextrin to be digested could limit the
risk of reduced absorption, by releasing the complexed compound
even at high cyclodextrin doses. This positive effect would only be
expected if it is assumed that the degradation of the cyclodextrin
does not lead to extensive precipitation of the compound. The
fact that g-cyclodextrin is degradable in the intestinal lumen as
well as its high aqueous solubility and larger cavity size makes it a
potentially excellent drug formulation candidate, but this could
also lead to a different biopharmaceutical profile.10
This study investigated the effect of HP-b-cyclodextrin and
g-cyclodextrin on the oral absorption of benzo[a]pyrene; g-
cyclodextrin was of interest mainly due to its degradability
explained above, while 2-HP-b-cyclodextrin was chosen as a
reference. Benzo[a]pyrene was selected as the model because it
enables a straightforward comparison with the results presented
by Westerberg and Wiklund.12 The purpose of this study was (1)
to explore how the oral administration of escalating doses of
cyclodextrins affect the absorption of benzo[a]pyrene and (2) to
investigate how the different degradation profiles of b-cyclodex-




2-HP-b-cyclodextrin (degree of substitution 4.55, for character-
ization of the batch see Holm et al.15) was purchased from Roquette
(Lestrem, France). g-Cyclodextrin was purchased from Wacker
Chemie (München, Germany) and both cyclodextrins were of
pharmaceutical grade. [3H]benzo[a]pyrene for the in vivo study was
obtained in toluene from Biotrend with a specific radioactivity of 50
Ci/mmol (1.85 TBq/mmol). OptiPhase SuperMix® liquid scintillator
was from PerkinElmer (Waltham, MA). The water used in the ex-
periments was obtained from a Millipore purification system. All
other chemicals used were of analytical grade.
Formulations for In Vivo Study
An ethanol solution of [3H]benzo[a]pyrene was prepared by
evaporation of the toluene in which it was delivered at room
temperature under a stream of nitrogen. After all toluene was
evaporated the solid matter left in the tube was dissolved in 96%
ethanol.The animals received a dose of a placebo cyclodextrin solu-
tion by oral gavage the day before and immediately before
administration of benzo[a]pyrene. This was prepared by weighing
appropriate amounts of dried cyclodextrin (dried at vacuum for
48 h before weighing). Water was then added and the solution
stirred until all cyclodextrin had dissolved and finally adjusted to
the correct volume. This solution was dosed at 10 mL/kg and the
animals received 0, 3, 30, 400, 500, 1000, 1500, or 2000 mg/kg of
either cyclodextrins. In addition, 2500, 3000, and 5000 mg/kg
were dosed for 2-HP-b-cyclodextrin and 2300 mg/kg for g-cyclo-
dextrin, a difference based on the solubility of the 2 cyclodextrins.
After the cyclodextrin solution was dosed, an ethanol solution of
[3H]-benzo[a]pyrene was administered by oral gavage at a dose of
1050 ng/kg (250 mCi/kg) in a volume of 0.3 mL/kg.
Experimental Design of the In Vivo Study
The protocol used for the rat in vivo studies was approved by
the institutional ethics committee in accordance with Danish
law regulating experiments on animals and in compliance with
EU directive 2010/63/EU, and the NIH guidelines on animal
welfare. Male Sprague-Dawley rats were purchased from Charles
River Deutschland (Sulzfeld, Germany). The animals were accli-
matized and maintained on standard feed and carrots with free
access to water for a minimum of 5 days prior to the experi-
ments. At initiation of the experiments the rats had an average
weight of 286-324 g. The study used a protocol similar to the
one described by Westerberg and Wiklund,12 with the exception
that the cyclodextrin was dosed in 10 mL/kg instead of the
20 mL/kg.
All groups consisted of 6 randomly assigned male rats and
each received a placebo cyclodextrin solution with either HP-b-
cyclodextrin or g-cyclodextrin 24 h in advance and again immedi-
ately before a single oral dose of [3H]benzo[a]pyrene (1050 ng/kg
equal to 250 mCi/kg). All rats were fasted overnight prior to [3H]-
benzo[a]pyrene dosing and ad libitum access to food was restored
8 h after dosing and for the rest of the experiment. Blood samples
were collected following oral administration of [3H]-benzo[a]pyrene
and the animals were euthanized after the last blood sample was
taken. The blood samples (200 mL) were withdrawn from the tail
vein at 0, 0.5, 1, 2, 4, 8, 24, 32, 48, 72, 120, and 168 h after dosing.
Plasma was immediately separated by centrifugation at 3600  g
for 10 min and stored in polypropylene tubes at 80C until
analyzed.
Bioanalysis
Plasma samples were thawed and were subsequently mixed
with the scintillation cocktail and counted directly using a Perkin-
Elmer (TriCarb 2900TR). Quench correction was based on external
radioactivity standards. The samples were counted for 3 min. Blank
counts were concurrently measured and used for background
correction. The blank values originated from plasma withdrawn
before dosing.
Pharmacokinetic Analysis
The pharmacokinetic parameters characterizing oral adminis-
tration of benzo[a]pyrene were obtained by noncompartmental
analysis using WinNonlin Professional version 5.2 (Pharsight Cor-
poration, Mountain View, CA). The area under the curve for benzo
[a]pyrene after oral administration (AUC0-last) was calculated using
the linear trapezoidal rule from time zero to the last measured
plasma concentration postdose.
Table 1
Pharmacokinetic Parameters Obtained after Oral Administration of [3H]benzo







0 5.2 ± 1.9 647 ± 42a 32,594 ± 1584a
3 5.1 ± 1.0 612 ± 64 29,543 ± 1629b
c
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SigmaPlot for Windows version 11.2.0.5 (Sysstat Software Inc.,
San Jose, CA) was used for the statistical calculations. The statistical
difference between the groups was compared by one-way analysis
of variance followed by comparison using the Dunn's method. p
Values below 5% (p < 0.05) were considered statistically significant.30 5.5 ± 1.1 575 ± 58 28,308 ± 1881
400 3.9 ± 0.9 496 ± 66 19,090 ± 985
500 3.4 ± 0.9 559 ± 66 22,609 ± 712
1000 5.8 ± 3.3 427 ± 47 20,286 ± 1039
1500 8.4 ± 3.3 523 ± 85 24,729 ± 1664
2000 7.3 ± 0.7 543 ± 26 23,773 ± 1314
2300 6.0 ± 0.9 561 ± 48 24,310 ± 872
Data presented as mean ± standard error (n ¼ 6; n ¼ 11 for 0 mg/kg).
a Statistically significantly different from the animals receiving 400, 500,
1000, 1500, 2000, and 2300 mg/kg g-cyclodextrin.
b Statistically significantly different from the animals receiving 400, 500, and
1000 mg/kg g-cyclodextrin.
c Statistically significantly different from the animals receiving 400 and
1000 mg/kg g-cyclodextrin.Results and Discussion
Coadministration of g-Cyclodextrin
The average plasma concentration as a function of time for
benzo[a]pyrene after coadministration with g-cyclodextrin is
shown in Figure 1 and the associated pharmacokinetic parameters
are given in Table 1. Individual curves for each cyclodextrin con-
centration are in the supporting information.
No statistical difference between the groups was observed for
tmax. The Cmax for the control group (0 mg/kg) was significantly
higher than the groups coadministered with 400 mg/kg or more of
g-cyclodextrin. The lower Cmax at higher g-cyclodextrin concen-
trations was probably due to the lower bioavailability of benzo[a]
pyrene and the need for a longer absorption time, as less compound
was available in the free form due to complexation with cyclo-
dextrin. Before the compound could be absorbed it would need to
be expelled from the cyclodextrins, which in accordance with Le
Châtelier's principle occurs both through dilution, by a competitive
replacement by intestinal bile salts13 and potentially through
digestion of the g-cyclodextrin.10 The decrease in Cmax observed in
this study started at much higher concentrations than reported by
Westerberg and Wiklund,12 who coadministered benzo[a]pyrene
with natural b-cyclodextrin, and the Cmax decrease (up to approx-
imately a factor of 1.5) was relatively smaller than the decrease
reported (up to a factor of 5.5) by Westerberg and Wiklund,12
indicating that g-cyclodextrins could induce a different biophar-
maceutical processing than the nondigestible b-cyclodextrin.
The AUC was also significantly higher in the control group
than in the animals coadministered with 400 mg/kg or more g-
cyclodextrin, in accordance with the findings for Cmax. Also the
animals dosed with 3 and 30 mg/kg had a significantly higher ab-
sorption than some of the groups dosed with higher cyclodextrinFigure 1. Total radioactivity plasma concentration time profile of [3H]benzo[a]pyrene
following single oral administration of 1050 ng/kg (250 mCi/kg) to rats with coad-
ministration of (:) 0, (;) 3, (-) 30, (△) 500, (>) 2000, and (B) 2300 mg/kg of
g-cyclodextrin (shown in the legend). Data are presented as mean ± standard error
(n ¼ 6, 11 for 0 mg/kg)concentrations and a clear trend for different AUC values was
observed for the animals coadministered 0, 3, and 30 mg/kg versus
400 mg/kg and above, although not significantly for all groups.
There was no difference in the elimination rate constant and no
difference was observed between the groups (data not shown), that
is, the observed differences were a reflection of different amounts
of benzo[a]pyrene absorbed and not a reflection of different elim-
ination kinetics. The relative decrease in AUC was up by a factor
of 1.7 in this study, whereas Westerberg and Wiklund12 reported
a difference of more than a factor of 15 for the highest
cyclodextrin dose.
The use of benzo[a]pyrene in this study was selected based on
the study published by Westerberg and Wiklund,12 where an
extensive decrease in absorption was reported when coad-
ministered with natural b-cyclodextrin. As benzo[a]pyrene has
been reported to have nonlinear pharmacokinetics,16-18 partic-
ularly at concentrations above 200 mM,19 it was decided to
deploy a dose regime similar to that of Westerberg and
Wiklund,12 that is, a low dose of radioactive compound was
selected. Foth et al.,17 after oral dosing of radiolabeled benzo[a]
pyrene, have demonstrated that only 30% of the total radioac-
tivity corresponds to the unmetabolized compound at the peak
concentration after oral dosing of radiolabelled benzo[a]pyrene.
In this study, only the total drug-related radioactivity was
measured, hence the study did not reveal any differences in
metabolic pattern that may occur through coadministration of
different cyclodextrins or amounts of cyclodextrins. The total
radioactivity counted was still a reflection of the total fraction
absorbed despite the subsequent metabolic fate of the com-
pound and could therefore be used in the evaluation of influence
on the total bioavailability.
Besides differences between g-cyclodextrin and b-cyclodextrins
in their potential intestinal digestibility,10 other differences in the
release mechanism could potentially occur. The release mechanism
of a compound from a cyclodextrin complex upon oral adminis-
tration has been suggested to be a combination of dilution, which
must be assumed to be constant across groups, and competitive
displacement by bile salts present within the intestinal tract,20,21
that is, differences in stability constants between cyclodextrins of
both compound and bile salts may in theory influence the release
and thereby the absorption. To the best of our knowledge, the
stability constant between b-cyclodextrin and benzo[a]pyrene has
not been determined, but the apparent stability constants
measured by phase solubility studies has been reported for
Table 2
Pharmacokinetic Parameters Obtained After Oral Administration of [3H]benzo[a]







0 5.2 ± 1.9 647 ± 42a 32,594 ± 1585d
3 4.8 ± 0.9 612 ± 66b 32,215 ± 2232c
30 2.8 ± 0.3 586 ± 41c 28,674 ± 1248c
400 8.7 ± 3.2 365 ± 26 19,089 ± 962
500 3.7 ± 0.9 524 ± 78 21,376 ± 2015
1000 6.4 ± 1.0 407 ± 62 20,278 ± 1736
1500 10.8 ± 4.3 420 ± 53 20,288 ± 1320
2000 5.8 ± 1.0 395 ± 34 20,273 ± 866
2500 8.0 ± 0.0 347 ± 50 20,160 ± 2040
3000 6.2 ± 1.2 406 ± 40 19,899 ± 1210
5000 7.3 ± 0.7 276 ± 21 16,046 ± 850
Data presented as mean ± standard error (n ¼ 6, n ¼ 11 for 0 mg/kg).
a Statistically significantly different from the animals receiving 400, 1000, 1500,
2000, 2500, 3000, and 5000 mg/kg HP-b-cyclodextrin.
b Statistically significantly different from the animals receiving 2500 and 5000
mg/kg HP-b-cyclodextrin.
c Statistically significantly different from the animals receiving 5000mg/kg HP-b-
cyclodextrin.
d Statistically significantly different from the animals receiving 400, 2500, and
5000 mg/kg HP-b-cyclodextrin.
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value measured in the presence of 15 mM sodium taurocholate,
that is, with competitive interaction. For g-cyclodextrin, we have
found an apparent stability constant of 37,050 M1 at 37C in a
phase solubility study (data not shown); the relative affinity of
benzo[a]pyrene toward the 2 different classes of cyclodextrins was
in the same range. In this study, benzo[a]pyrene was administered
solubilized in ethanol and 100 mL was dosed to each rat, theoreti-
cally affecting the stability constants. However, the gastric volumes
in rats of ~300 g have been reported to be 2.4 mL by Takashima
et al,24 which provide a dilution of the administered ethanol to <5%
vol/vol, which must be assumed to have limited influence for the
compound’s relative affinity toward the cyclodextrin. Also when
looking at the affinity of the bile salts, Holm et al.15,25,26 have re-
ported similar affinities between both HP-b-cyclodextrins and g-
cyclodextrins and bile salts relevant for rats; a difference in the
performance of the 2 types of cyclodextrins would therefore
probably be a reflection of differences in biopharmaceutical per-
formance rather than differences in the physical chemical in-
teractions with key components. This study therefore indicates that
g-cyclodextrins performed better than b-cyclodextrins, when
compared with the data of Westerberg and Wiklund.12Coadministration of 2-Hydroxypropyl-b-Cyclodextrin
Due to the risk of interstudy comparison and as substituted b-
cyclodextrins are more used than natural b-cyclodextrin, due to
their higher solubility and lower toxicity, this study also included
an investigation of how HP-b-cyclodextrin performed when coad-
ministrated with benzo[a]pyrene. The average plasma concentra-
tion as a function of time for benzo[a]pyrene after coadministration
with HP-b-cyclodextrin is shown in Figure 2 and the associated
pharmacokinetic parameters are given in Table 2. Individual curves
for each cyclodextrin concentration can be found in the supporting
information.
No significant difference was found between any of the treat-
ments with respect to tmax, whereas differences were observed
for both Cmax and AUC, where those groups coadministered with
the lower amounts of 2-HP-b-cyclodextrin had higher Cmax and
AUC values than the animals dosed with higher amounts of 2-HP-
b-cyclodextrin. Extensive coadministration of HP-b-cyclodextrinFigure 2. Total radioactivity plasma concentration time profile of [3H]benzo[a]pyrene
following single oral administration of 1050 ng/kg (250 mCi/kg) to rats with coad-
ministration of (:) 0, (;) 3, (-) 30, (△) 500, (>) 2000, (B) 3000, AND (7)
5000 mg/kg of HP-b-cyclodextrin (shown in the legend). Data are presented as
mean ± standard error (n ¼ 6, 11 for 0 mg/kg).could therefore limit the bioavailability of a compound as reported
byWesterberg andWiklund for b-cyclodextrin.12 When compared
with the data obtained when benzo[a]pyrene was coadministered
with g-cyclodextrin, it is noticeable that the decrease was
approximately in the same range, that is, less than a factor 2. This
study therefore suggests that very high doses of both 2-HP-b-
cyclodextrin and g-cyclodextrin have a negative impact on the
bioavailability of benzo[a]pyrene, but there was no difference
between the 2 types of cyclodextrins. The amount of benzo[a]
pyrene dosed in this study was as low as 4.2 nmol/kg. Significant
decreases in the absorption of benzo[a]pyrene were not seen until
400 mg/kg of one of the 2 cyclodextrins was dosed (equal to
approximately 0.2 mmol/kg). Thus, the molar difference was
>50,000 before the oral bioavailability of benzo[a]pyrene was
significantly reduced. Overdose of cyclodextrin in these quantities
would not be relevant in most oral applications, and based on the
present data the danger of oral cyclodextrin overdosing should be
considered only in extreme cases. The presence of high concen-
trations of cyclodextrin will lower the fraction of free and
uncomplexed compound,27 but a proportion of the dose will be
present in the free form and available for oral absorption, which
seems sufficient to drive absorption.
The dose of benzo[a]pyrene in this study was chosen in order
to compare the results with those reported by Westerberg and
Wiklund,12 as discussed above. Furthermore, the doses of cyclo-
dextrins were selected to be in the range over which Westerberg
and Wiklund12 observed a decline in absorption, which was
as low as 5 mg b-cyclodextrin/kg. In this study, a significant
reduction was not observed until 400 mg/kg cyclodextrin. The
reason for this difference was not clear, but a possible explanation
could be the differences in degree of dilution of the doses
administered. In this study, the cyclodextrin was dosed in
a volume of 10 mL/kg, while Westerberg and Wiklund12 used
20 mL/kg. This change was induced due to ethical reasons as
described in good practices for studies in rodents.28 The coad-
ministration of a higher volume will lead to another dilution
factor of the cyclodextrin and potentially to a different intestinal
transit time affecting the overall absorption of benzo[a]pyrene.
Another potential explanation could be that benzo[a]pyrene
forms an insoluble complex with b-cyclodextrin, but not with
the more soluble 2-HP-b-cyclodextrin or g-cyclodextrin, although
N.E. Olesen et al. / Journal of Pharmaceutical Sciences 105 (2016) 2698e27022702in vitro data suggest that this is not the case.22 This hypothesis
may also explain why there are no stability constants between
benzo[a]pyrene and natural b-cyclodextrin in the literature and
why we observed very low concentrations of benzo[a]pyrene
when the phase solubility study was conducted (data not shown).
Another potential reason for the difference could be a different
diffusion of the cyclodextrins through the unstirred water
layer.29,30 The 2 highly soluble cyclodextrins, HP-b-cyclodextrin
and g-cyclodextrin, may have an easier passage through the
unstirred water layer than the poorly soluble b-cyclodextrin,
resulting in a lower bioavailability for benzo[a]pyrene when
coadministered with these cyclodextrins.
This study suggests that there is a small limited biopharma-
ceutical difference between a digestible and a nondigestible
cyclodextrin. Lumholdt et al.10 demonstrated that the digestion rate
of g-cyclodextrin in vitro was reduced when benzo[a]pyrene was
present, which could reflect that the chemical equilibrium was
faster than the enzymatic process and that enzymatic degradation
was not possible when a compound was complexed within the
cyclodextrin cavity. This mechanism could reduce the biopharma-
ceutical advantage, as observed in this study; however, these
findings must be confirmed with other compounds, to ensure that
it was not a benzo[a]pyrene-specific effect. More interestingly, this
study also suggested that the risk of overdosing cyclodextrins may
be lower than originally thought based on the study published by
Westerberg and Wiklund.12 This suggests that cyclodextrins can be
used in excess without losing too much bioavailability for orally
administered compounds, at least for highly permeable compounds
such as benzo[a]pyrene. A better theoretical understanding of the
system is still desirable as well as validationwith other compounds
at doses more relevant for most drug compounds.
Conclusions
In conclusion, this study has investigated the influence of
oral coadministration of either 2-HP-b-cyclodextrin or g-cyclo-
dextrin in escalating doses on the absorption of benzo[a]pyrene
to see if the digestibility of the cyclodextrin had an influence
of the absorption of benzo[a]pyrene. The in vivo studies demon-
strated a decreased absorption of low doses of benzo[a]pyrene
when >400 mg/kg cyclodextrin was coadministered with the
compound. The maximum decrease in the absorptionwas less than
a factor 2. Themechanism leading to this phenomenonwas thought
to be a result of a strong interaction between the cyclodextrins and
benzo[a]pyrene in combination with the limited amount of bile
salts in the intestine ensuring displacement from the cyclodextrin
cavity. No differences were observed between the 2 investigated
cyclodextrins, that is, potential digestibility did not seem to be
beneficial from a biopharmaceutical perspective.
The coadministration of 2-HP-b-cyclodextrin and g-cyclodex-
trin led to significant lower reduction in the bioavailability when
compared with data in the literature. This was suggested to be a
reflection of formation of a poorly soluble complex between benzo
[a]pyrene and natural b-cyclodextrin, which precipitated thereby
leading to the low absorption. This was not observed with the more
aqueous soluble cyclodextrins used in this study. Caution should
still be taken when defining the cyclodextrin in a new formulation;
though these findings suggest that the risk of overdosing with cy-
clodextrins may be lower than initially suggested.
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